Research Article: The Eeffect of Metformin Combined with Calcium-Vitamin D3 Against Diet-Induced Nonalcoholic Fatty Liver Disease

Date Published: March 18, 2018

Publisher: Tabriz University of Medical Sciences

Author(s): Sara Shojaei Zarghani, Samin Abbaszadeh, Mohammad Alizadeh, Maryam Rameshrad, Alireza Garjani, Hamid Soraya.

http://doi.org/10.15171/apb.2018.012

Abstract

Purpose: Metformin is one of the most popular drugs tested against nonalcoholic fatty liver disease (NAFLD). The present study aimed to investigate whether calcium-vitamin D3 cosupplementation will intensify the effect of metformin on the prevention of high-fat, high-fructose (HFFr) diet-induced hepatic steatosis.

Partial Text

Nonalcoholic fatty liver disease (NAFLD) has become the most common form of chronic liver disease in the world, which is characterized by abnormal triglyceride accumulation in hepatocytes, not due to excess alcohol consumption or other causes of secondary hepatic steatosis.1,2 A growing body of evidence suggests a bidirectional relationship between NAFLD and components of metabolic syndrome,3,4 although insulin resistance may still play an important role in the pathogenesis of NAFLD.5 It is believed that insulin resistance and adiposity are associated with an imbalance between delivery and export of free fatty acid to the liver.1,5 Therefore,‏ it is not surprising that several studies have investigated the‏ efficacy of natural or pharmacological insulin sensitizers on the prevention and management of NAFLD.

In conclusion, our results suggest that both metformin and calcium-vitamin D3 provide similar hepatoprotective effects in an insulin and AMPK-independent manner, with slightly additional protective benefits of their combination on the steatosis scores and hepatic cholesterol content. Ultimately, the increased CTRP3 levels after metformin administration was also observed in the present study.

The authors would like to express their gratitude towards Dr. Amir Abbas Farshid and Dr. Ali Asghar Tehrani for conducting the pathological assessments. The authors would also like to thank the Pharma chemie, Arya and Daana Pharmaceutical Companies and Beyza 21 Feed Mill Company. Financially, this study was supported by Urmia University of Medical Sciences.

This study was conducted in accordance with the guide for care and use of laboratory animals approved by the Animal Ethical Committee of Urmia University of Medical Sciences.

The authors declare that they have no conflict of interest.

 

Source:

http://doi.org/10.15171/apb.2018.012

 

Leave a Reply

Your email address will not be published.